Long-term follow-up for a gene editing heart therapy
Part of Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study follows people who already received an experimental gene editing treatment for cardiovascular disease in a prior Verve trial. The goal is to monitor their health and any long-term effects over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in a Verve-sponsored clinical study and received at least one dose of their gene editing therapy.
- You agree to join this long-term follow-up study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medicine called VERVE-102 to lower cholesterol in people with or at high risk for heart disease. It may help reduce the risk of heart attacks and strokes by targeting a gene that affects cholesterol levels.
This trial tests a new medicine called VERVE-102 for people with a specific type of high cholesterol (HeFH) or early coronary artery disease. It aims to see if it can help lower cholesterol levels.
This trial tests a new one-time treatment called VERVE-201 for people with very high cholesterol or triglycerides that don't get better with standard medicines. The goal is to see if it can safely lower these fats in your blood.
This study tests a new injection called ART002g1 for people with an inherited form of high cholesterol (heterozygous familial hypercholesterolemia). The goal is to see if it is safe and can help lower cholesterol levels.
This trial tests a one-time gene therapy to lower extremely high cholesterol in people with a rare inherited condition. It may help reduce heart attack risk in those who haven't responded to standard treatments.
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Hear when a new Atherosclerotic Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.